NTLA Stock Price Today (July 2026) — Intellia Therapeutics, Inc. Analysis & Key Metrics 2026-07-17
Intellia Therapeutics, Inc. (NTLA) is trading at $11.38, down 4.09% today (as of July 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $26.63 (134.1% upside).
- Volatility remains elevated (62.40% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-9.50% YoY) alongside significant competitive pressures.
NTLA Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Intellia Therapeutics, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $2.07B
P/E Ratio
Forward P/E: -9.64
Revenue Growth
Year over Year
Analyst Target
+134.1% upside potential
Key Investor Questions About NTLA
What investors need to know before buying
Based on current market data, NTLA presents a oversold technical setup with challenging fundamentals.
- Technicals say: Oversold (RSI 22.57)
- Fundamentals say: Challenging (declining revenue trends)
NTLA's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NTLA investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $80.49M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, NTLA stock traded between $7.95 and $28.25—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 62.40% annualized volatility and β=1.73, the stock exhibits high sensitivity to market moves—making NTLA suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Intellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z Success
Why Intellia Therapeutics Stock Is Back in Focus Intellia Therapeutics (NTLA) is back on investors’ radar after announcing successful Phase 3 trial results for its gene editing treatment Lonvo-z and outlining plans for a future U.S. launch. These clinical milestones mark a clear step toward potential commercialization and broader market reach. This has coincided with renewed interest in Intellia Therapeutics stock performance and valuation in recent months. See our latest analysis for...
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.
Intellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On Returns
Intellia Therapeutics has staged a sharp rebound in 2026, yet its long term track record and current valuation checks suggest the stock may still be priced with little room for disappointment. The recent surge around its in vivo CRISPR program sits against a weaker 5 year return profile and a low value score. Over the past 5 years, Intellia Therapeutics has delivered a decline of 88.1%, which puts the recent recovery into context as a rebound rather than a clear long term win so far. The...
Wall Street Doubles Down on Wolfspeed Short Positions Over Cash Burn Fears
WOLF is now Wall Street's most shorted stock. Here's why bears keep piling on even after Wolfspeed's big debt overhaul.
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
This new technology could one day significantly expand the market for gene-editing biotechs.
Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy Now?
Is NTLA a good stock to buy? We came across a bullish thesis on Intellia Therapeutics, Inc. on Markman Capital Insight’s Substack. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.’s share was trading at $16.61 as of June 29th. Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on […]
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
It might pull it off, provided several things fall right in place.
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare.
This Stock Is Up 58% This Year. Is It too Late to Buy?
There could be additional catalysts for this drugmaker over the next year.
Frequently Asked Questions
Common investor questions about Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. (NTLA) is currently trading at $11.38. The RSI (14-day) is at 22.6, indicating oversold territory (potentially undervalued). Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $26.63 implies 134.1% upside from current levels. Volatility is high at 62.4% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Intellia Therapeutics, Inc. (NTLA): The trailing P/E ratio is -3.23, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -9.64, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 2.21. Price-to-Sales is 24.05. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 19 analysts covering NTLA, the consensus price target is $26.63. This represents a 134.1% upside from the current price of $11.38. The range spans from a low target of $8.00 to a high target of $95.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Intellia Therapeutics, Inc. (NTLA) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Intellia Therapeutics, Inc. (NTLA) investors include: 1. High volatility (62.4% annualized)—the stock can experience significant daily price swings. 2. Declining revenue (-9.5% YoY), indicating potential business headwinds. 3. Elevated short interest (45.4% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Intellia Therapeutics, Inc.'s (NTLA) current debt and financial health profile: Total debt stands at $80.49M. The debt-to-equity ratio is 12.96, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 6.10, indicating strong short-term liquidity. The quick ratio is 5.04. The company holds $375.99M in cash and equivalents. Free cash flow is negative at $-235,232,880, which could limit the company's ability to manage debt obligations.